Drug class
Preferential Janus kinase 1 (JAK1) inhibitor; targeted synthetic immunomodulator
Mechanism of action
ATP-competitive and reversible inhibitor of the JAK family, with preferential inhibition of JAK1 over JAK2, JAK3 and TYK2. This reduces phosphorylation and activation of STAT transcription factors downstream of multiple inflammatory cytokine receptors.
General use cases
- Treatment of moderate-to-severe active rheumatoid arthritis in adults with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs; monotherapy or in combination with methotrexate
- Treatment of moderately-to-severely active ulcerative colitis in adults after inadequate response, loss of response or intolerance to conventional or biological therapy; use is subject to product-specific warnings and eligibility restrictions
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
